Eli Lilly (LLY) will report its third-quarter 2024 earnings on Oct. 30, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $12.03 billion and $1.53 per share, respectively.The strong sales performance of its FDA-approved tirzepatide medicines, diabetes drug Mounjaro and weight loss medicine, Zepbound, helped Lilly deliver exceptionally strong results in the last report quarter. We expect the trend to continue in the third quarter.Tirzepatide is a dual GIP and GLP-1 receptor ...

Eli Lilly and Co LLY will be reporting its third-quarter earnings on Wednesday. Wall Street expects $1.45 in EPS and $12.10 billion in revenues as the company reports at 10 a.m. ET.Is A Stock Split On The Horizon For This Weight Loss Drug Maker?The stock is up 58.31% over the past year, 51.23% YTD. Eli Lilly’s stock has experienced a remarkable rise, recently trading close to $900 a share, down from a record high of about $972. This surge, especially from just $250 two years ago, positions Lilly for a poten ...

One key disease-prevention market is drawing closer to being within reach. As if there weren't enough reasons to buy shares of the cardiometabolic drug juggernauts Eli Lilly (LLY 0.32%) and Novo Nordisk (NVO -0.90%), there's now one more big reason to expect these two stocks to keep climbing. While this new opportunity will take some time to cook before it's ready to delight shareholders, one of the two companies is making significant headway, so it won't be much longer in the grand scheme of things. Here's ...

The odds of its new drug getting established in the U.K. are now much lower.Everyone knows that big pharma companies like Eli Lilly (LLY 0.32%) need to get regulators to agree that their medicines are safe and effective before they can make any money. But regulators aren't the only group the companies need appease before shareholders can see a return.And sometimes, those other groups can throw a wrench into the works, damping long-term growth. As of now, it's looking like Lilly might have stumbled into a pi ...

Analyst Estimates for Q3 2024 Q2 2024 Q3 2023 Revenue $12.18 billion $11.3 billion $9.50 billion Earnings Per Share (Loss) $1.87 $3.28 (6 cents) Net Income (Loss) $1.69 billion $2.97 billion ($57.4 million) Key Metric: Research and Development Costs, Guidance Ahead of Wednesday's earnings announcement, Eli Lilly said it expects to report an IPR&D charge of about $2.83 billion for the quarter, well above the $154 million and $111 million, respectively, the company reported for the first two quarters of the y ...

Eli Lilly logo is screened on a mobile phone for illustration photo. Krakow, Poland on April 9th, ... [+] 2024 (Photo by Beata Zawrzel/NurPhoto via Getty Images) NurPhoto via Getty Images Eli Lilly stock (NYSE: LLY) will report its Q3 results on Wednesday, October 30. The pharmaceutical giant is expected to garner $12.1 billion in sales and $1.45 in adjusted earnings per share, per the consensus estimates. All eyes will be on Eli Lilly's diabetes drug – Mounjaro – and its weight-loss drug – Zepbound. In thi ...

At three years, over 80% of patients with moderately to severely active UC who were in remission with mirikizumab sustained long-term remission and relief from disruptive symptoms, including bowel urgencyMirikizumab also helped over 50% of patients with moderately to severely active Crohn's disease sustain long-term endoscopic remission for up to five years INDIANAPOLIS, Oct. 28, 2024 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced results from two, multi-year, Phase 3 studies that showed patien ...

Core Insights - ViaNautis Bio has entered a strategic collaboration with Eli Lilly to utilize its polyNaut® platform for developing targeted genetic medicines [1][2] - The collaboration includes an initial upfront payment and potential future milestone payments based on research achievements and commercialization of products [2] - The polyNaut® technology aims to enhance the delivery of genetic materials, potentially transforming treatment options for various diseases [3][6] Company Overview - ViaNautis Bio, founded in 2018 as a spin-off from UCL, focuses on leveraging its polyNaut® technology for targeted genetic medicine delivery [5] - The polyNaut® platform is designed for precise intracellular delivery, capable of encapsulating a wide range of genetic cargoes and small molecules [6] - The technology distinguishes itself by effectively targeting specific cells and overcoming biological barriers, including the blood-brain barrier [7] Collaboration Details - The collaboration with Lilly is expected to accelerate the development of novel therapies for severe life-limiting diseases by combining ViaNautis' scientific expertise with Lilly's drug development capabilities [4] - ViaNautis is actively building an internal pipeline while collaborating with other pharmaceutical and biotech companies to explore new therapeutic platforms [8]

Stanley Druckenmiller's Duquesne Family Office exited its position in Eli Lilly stock last quarter.Some hedge funds have a tendency to move on from their holdings in short order in an effort to book profits and redeploy capital into a new higher-conviction opportunity. According to its recent 13F filing, the Duquesne Family Office headed by billionaire portfolio manager Stanley Druckenmiller closed out 28 positions in total last quarter -- and one of these moves really stood out.Last quarter, Druckenmiller' ...

These two companies -- leaders in their industries -- look unstoppable. Just because a stock is beating the market doesn't mean it's no longer worth investing in. As long as a company has a solid business and excellent growth prospects, investors can count on it to deliver solid returns over the long run. So, despite many companies performing exceedingly well in the current bull market we're experiencing, some remain top picks. Here are two examples: Eli Lilly (LLY 0.15%) and Netflix (NFLX 0.02%). Both stoc ...